Ecolab Schedules Webcast of Industry Conference for June 3, 2025
ST. PAUL, Minn.--(BUSINESS WIRE)--Christophe Beck, Ecolab's chairman and chief executive officer, will address financial analysts at the William Blair Growth Stock Conference on Tuesday, June 3, 2025. Ecolab will offer a webcast of Mr. Beck's presentation. Details for the webcast are as follows:
To access the webcast, visit the Events & Presentations section of Ecolab's Investor website at www.ecolab.com/investor and click on the webcast details.
About Ecolab
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab's innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets. www.ecolab.com
Follow us on LinkedIn @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.
(ECL-C)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Yahoo
2 hours ago
- Yahoo
Eversource Energy (NYSE:ES) Launches US$1.2 Billion Follow-on Equity Offering
Eversource Energy recently filed a $1.2 billion follow-on equity offering, reflecting its strategy to bolster its financial position through capital raising. Over the past month, the company's shares increased by 9%, aligning with the broader market trend, which also saw an upward momentum, rising 1.7% over the last week. Eversource's dividend affirmation and steady earnings announcements complement its robust performance. These financial maneuvers likely added weight to the company's share price movement, reinforcing investor confidence alongside broader market strength, where annual earnings are expected to grow by 14%. Be aware that Eversource Energy is showing 3 risks in our investment analysis and 2 of those can't be ignored. Rare earth metals are the new gold rush. Find out which 24 stocks are leading the charge. The recent $1.2 billion equity offering by Eversource Energy strengthens its financial position, potentially enabling further investments in Massachusetts' transmission and distribution infrastructure. Although the company's shares increased by 9% in the past month, the long-term return over the last year, including both share price appreciation and dividends, was 14.73%. This is noteworthy, given that Eversource underperformed the US Electric Utilities industry, which returned 12.8% over a 1-year period, highlighting a stronger performance in a shorter timeframe. Looking ahead, this capital infusion may positively impact revenue and earnings forecasts, aligning with the anticipated 4.0% revenue growth and increased profit margins over the next three years. The follow-on equity offering could alleviate some pressure from regulatory uncertainties, inflationary pressures, and supply chain challenges, potentially aiding operational efficiency and future earnings stability. Analysts suggest a fair value price target of US$69.27 for Eversource, which is higher than the current share price of US$59.21, indicating a potential upside if their growth assumptions hold true. However, the market remains divided, with price targets ranging from US$47 to US$85. Investors should consider these various factors and assumptions when evaluating the company's long-term value. Gain insights into Eversource Energy's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ES. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 hours ago
- Yahoo
Reddit (NYSE:RDDT) Sees 11% Price Rise Following Q1 Earnings Turnaround
Reddit recently integrated with Smartly, enhancing its advertising capabilities and influence over consumer purchasing decisions, potentially influencing its impressive 11% price rise last week. This integration, paired with robust Q1 2025 earnings showing significant revenue growth and a transition from loss to positive net income, signals strong operational progress. These developments are aligned synergistically against an overall market increase of 2% over the same period. Such corporate advancements add weight to Reddit's price movement, reflecting positive sentiment and reinforcing market confidence in its growth trajectory and advertising potential. Every company has risks, and we've spotted 1 warning sign for Reddit you should know about. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Reddit's integration with Smartly has not only led to an immediate share price increase but also aligns with the company's larger growth narrative. The move supports expansion in advanced ad solutions and enhances Reddit's appeal across key international markets, potentially bolstering revenue streams and profitability. Over the past year, Reddit's shares saw a remarkable total return of 107.14%, showcasing its robust performance against the US Interactive Media and Services industry, which achieved a lower return of 12%. This outperformance is indicative of Reddit's growing influence and successful monetization efforts. The integration and recent earnings advancements project further positive impacts on revenue and earnings forecasts. Analysts anticipate Reddit's revenue will grow consistently, with an expectation that earnings may exceed US$770 million by 2028. Despite the current share price of US$104.62, the analyst price target of US$150.25 reflects a potential 30.4% increase, highlighting market confidence in Reddit's strategic initiatives. As Reddit continues to leverage Smartly's capabilities, the company's trajectory suggests possible sustained profitability, with implications for competitive positioning in the global market. Upon reviewing our latest valuation report, Reddit's share price might be too optimistic. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:RDDT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
